Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy

Jingpei Li; Ke Xu; Weipeng Cai; Yalei Zhang; Xin Zeng; Fei Cui; Zhexue Hao; Jun Liu; Jianxing He

doi:10.3389/fonc.2020.01145

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy

Front Oncol. 2020 Jul 16:10:1145. doi: 10.3389/fonc.2020.01145. eCollection 2020.

Authors

Jingpei Li^{1

2

3}, Ke Xu^{1

2

3}, Weipeng Cai^{1

2

3}, Yalei Zhang^{1

2

3}, Xin Zeng⁴, Fei Cui^{1

2

3}, Zhexue Hao^{1

2

3}, Jun Liu^{1

2

3}, Jianxing He^{1

2

3}

Affiliations

¹ Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
² Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China.
³ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China.
⁴ Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Abstract

We report a case of successful neoadjuvant four-drug combination therapy to avoid total pneumonectomy. A 33-year-old male patient was diagnosed with locally advanced non-squamous NSCLC harboring EGFR mutation in the left lower lobe. The patient experienced significant clinical downstaging after two cycles of neoadjuvant therapy, including icotinib, carboplatin, pemetrexed, and bevacizumab. He underwent a successful lobectomy avoiding pneumonectomy. The patient showed no recurrence in the follow-up of a chest computed tomographic scan, which is 17 months after surgery. The promising results of this neoadjuvant combination therapy provided a novel therapeutic option for patients with locally advanced EGFR-mutated NSCLC facing total pneumonectomy.

Keywords: EGFR mutation; chemothearpy; neoadjuvant; surgery; targeted (selective) treatment.

Publication types

Case Reports